GSK, Pfizer and RSV
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.
Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...
The stock's fall snapped a two-day winning streak.
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...
The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
Pfizer (PFE) closed the most recent trading day at $26.91, moving -0.83% from the previous trading session. This change lagged the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback